Last reviewed · How we verify
HBVAXPRO™
At a glance
| Generic name | HBVAXPRO™ |
|---|---|
| Also known as | Hepatitis B virus (HBV) vaccine; V232 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384
- Hepatitis B Vaccine Delivered Trans-dermally by MAP (PHASE1)
- A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) (PHASE3)
- Hepatitis B Challenge Dose in Adults (V232-059-10) (PHASE3)
- A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013) (PHASE3)
- A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBVAXPRO™ CI brief — competitive landscape report
- HBVAXPRO™ updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI